Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-25T05:06:13.151Z Has data issue: false hasContentIssue false
  • English
  • Français

Liposarcoma of the left hemithorax and implications of MDM2

Published online by Cambridge University Press:  28 May 2019

Michael Stolten Open the ORCID record for Michael Stolten [Opens in a new window] ,
Deepak Sahasrabudhe  and
Louis Constine
Michael Stolten*
Affiliation:
University of Rochester Medical Center, Rochester, USA
Deepak Sahasrabudhe
Affiliation:
University of Rochester Medical Center, Rochester, USA
Louis Constine
Affiliation:
University of Rochester Medical Center, Rochester, USA
*
Author for correspondence: Michael Stolten, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Use of molecular information to guide clinical management of thoracic liposarcoma following resection.

Case presentation:

We present a case of a large liposarcoma of the left hemithorax. Initial biopsy consistent with lipoma however following resection pathology showed well-differentiated liposarcoma. Clinical data and molecular information including MDM2 from the tumour were employed in decision making regarding subsequent adjuvant radiation therapy versus close observation.

Conclusion:

Improved molecular characterisation has increased the precision of histological diagnoses and prediction of outcomes for many cancers. These may continue to help guide and strengthen clinical decision making and recommendations as they pertain to adjuvant therapy versus observation in the case of this patient.

Keywords

adjuvant radiation therapyliposarcomaMDM2thorax
Type
Case Study
Information
Journal of Radiotherapy in Practice , Volume 18 , Issue 4 , December 2019 , pp. 397 - 399
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Nascimento, AG. Dedifferentiated liposarcoma. Semin Diagn Pathol 2001; 18 (4): 263–266.Google ScholarPubMed
Leach, FS, Tokino, T, Meltzer, P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53 (suppl 10): 2231–2234.Google ScholarPubMed
Boltze, C, Schneider-Stock, R, Jäger, V, Roessner, A. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. Pathol Res Pract 2001; 197 (8): 563–568.Google ScholarPubMed
Zhang, H, Erickson-Johnson, M, Wang, X, et al. Molecular testing for lipomatous tumors: critical analysis and test recommendations based on the analysis of 405 extremity-based tumors. Am J Surg Pathol 2010; 34 (9): 1304–1311.10.1097/PAS.0b013e3181e92d0bCrossRefGoogle ScholarPubMed
Boltze, C, Schneider-stock, R, Jäger, V, Roessner, A. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. Pathol Res Pract 2001; 197 (8): 563–568.Google ScholarPubMed
Dei tos, AP, Doglioni, C, Piccinin, S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000; 190 (5): 531–536.10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W3.0.CO;2-W>CrossRefGoogle ScholarPubMed
World Health Organization. Adipocytic tumours. In: Fletcher, CDM, Bridge, JA, Hogendoorn, PCW, Mertens, F (eds). WHO Classification of Tumours of Soft Tissue and Bone, pp. 37–38. 4th edition. Geneva, Switzerland: WHO PRESS, 2013.Google Scholar
Ware, PL, Snow, AN, Gvalani, M, Pettenati, MJ, Qasem, SA. MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. Am J Clin Pathol 2014; 141 (3): 334–341.10.1309/AJCPLYU89XHSNHQOCrossRefGoogle ScholarPubMed
Linehan, DC, Lewis, JJ, Leung, D, Brennan, MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 2000; 18 (8): 1637–1643.10.1200/JCO.2000.18.8.1637CrossRefGoogle ScholarPubMed
Lahat, G, Anaya, DA, Wang, X, Tuvin, D, Lev, D, Pollock, RE. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol 2008; 15 (6): 1585–1593.10.1245/s10434-007-9805-xCrossRefGoogle ScholarPubMed